Abstract: New markers for determination of the high risk of NSCLC distant recurrence (distant metastases), where the markers are selected from the group of hsa.miR-192, hsa.miR-194, hsa.miR-662, hsa.miR-502.3p, hsa.miR-128 and hsa.miR-362.5p. A method for determination of the risk of distant recurrence (distant metastases) of NSCLC in surgically treated patients in stage I-IIIA after pulmonary resection, where: total RNA is isolated from a fragment of NSCLC tumor, the amount and quality of RNA in the examined sample are determined, with biotechnology methods of measuring the amount of microRNAs, preferably quantitative RT-PCR, the expression (amount) of microRNA in tumor tissue is determined; and, subsequently, the microRNA expression is analyzed according to the model of prediction of the occurrence of distant metastases, where the high expression of microRNAs: hsa.miR-192, hsa.miR-194, hsa.miR-662 and low expression of microRNAs: has.miR-502.3p, hsa.miR-128 and hsa.miR-362.

Abstract: A method of determination of the risk of distant metastases in surgically treated patients with non-small cell lung cancer in stage I-IIIA based on that a sample of primary tumor tissue is acquired, from which at least one microRNA is extracted which retrotranscripted into complementary DNA (cDNA) by reverse transcription, wherefore microRNA in examined sample is quantificated with the use of quantitative PCR method while the expression value of each microRNA is referred to the reference expression values in a recurrence prediction model in which the expression values are correlated to the high and low risk of distant metastases is characterized by that the expression value of only one from twenty two microRNAs listed below in Table 1 in primary tumor tissue of non-small cell lung cancer is measured.

Abstract: Aspects of the invention include methods for identifying patients with HER2+ cancers that are at a heightened risk for developing brain metastasis within three years of having been diagnosed with HER2+ cancer. Some embodiments are methods that include the steps of contacting at least a portion of the tumor tissue from patients with probes that interact with the products of a set of thirteen genes that are expressed in these patients at markedly higher levels than in similarly situated patients that are not a heightened risk for developing brain metastasis within this three year window. In some embodiments the tissue samples are assayed from the presence of RNA indicative of the expression of member of a set of 13 genes identified as being differentially expressed in patients with and without a heightened risk for developing brain metastasis.